|
Patent landscape, scope, and claims: |
Scope and Patent Landscape for US Patent 9,636,344 (Non-Hodgkin’s Lymphoma Method Claims for 2-Amino-Dihydroimidazoquinazoline Pyrimidine-5-Carboxamide Dihydrochloride Salt)
Executive summary: U.S. Patent 9,636,344 claims a method of treating non-Hodgkin’s lymphoma using a specific small-molecule active: 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide as a dihydrochloride salt (or solvate/hydrate/tautomer), with a further dependent claim to crystalline form and a dependent claim to combination therapy with a very broad list of oncology agents. The claim set is a classic “use” patent anchored to a single chemical species/salt form, so the enforceable scope will turn on (1) whether an accused regimen administers that exact drug entity (including salt form or recognized equivalents), (2) whether the regimen targets non-Hodgkin’s lymphoma, and (3) for combination exposure, whether the additional agent is among the listed options.
What is US Patent 9,636,344 claim scope for treating non-Hodgkin’s lymphoma with a dihydrochloride salt?
Core claim 1 (method claim)
- Claim type: Method of treatment (administering a therapeutically effective amount).
- Disease limitation: “a patient in need thereof” with non-Hodgkin’s lymphoma.
- Active limitation: a therapeutically effective amount of
2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt
or a solvate, hydrate or tautomer of that compound.
- Implication for scope: A practicing regimen that administers the compound (in claimed salt/solvate/hydrate/tautomer forms) to a non-Hodgkin’s lymphoma patient can fall within claim 1, even if the regimen is otherwise not branded to a specific regimen schedule, line of therapy, or specific lymphoma subtype unless the specification narrows those details.
Key interpretive levers
- “Administering” is broad: covers oral, parenteral, and any dosing form that yields systemic administration of the active species.
- “Therapeutically effective amount” is open-textured and typically litigated as a functional threshold, not a fixed mg level.
- “Solvate, hydrate or tautomer” expands beyond just the dihydrochloride crystalline material; it captures different physical states that still correspond to the claimed chemical entity family.
- No explicit dosing constraints in your provided claim text: the claim should be read as regimen-agnostic on schedule and amount, which increases infringement surface.
Does claim 1 cover all non-Hodgkin’s lymphoma subtypes or only certain indications?
Claim language effect
- The phrase “non-Hodgkin’s lymphoma” is not limited in the provided claim text by histology, molecular subgroup, or stage.
- If the specification includes examples or preferred embodiments tied to a specific NHL subtype, that would not automatically narrow the claim absent explicit claim dependency or clear claim construction limits.
Practical enforcement
- In litigation, defendants typically argue the claim should be confined to the indication actually supported by the patent disclosure or therapeutic use described. Courts, however, often treat method claims with disease language as broad unless the claim or specification imposes tight boundaries.
How much does crystalline-form language in claim 2 expand or narrow protection?
Dependent claim 2
- Builds on claim 1 by specifying that the dihydrochloride salt (or solvate/hydrate/tautomer) is “in crystalline form.”
Scope dynamics
- Claim 1 already covers the salt plus solvate/hydrate/tautomer, including potentially non-crystalline forms.
- Claim 2 narrows to crystalline material. That can matter in two ways:
- Commercial product differentiation: A manufacturer making an amorphous form or different solid-state form could argue non-infringement of claim 2 while still potentially falling into claim 1 if the active delivered is within claim 1’s covered set.
- Validity challenges: Solid-state-dependent claims are often targeted with prior art about polymorphs, crystallization, and known salts.
What does claim 3 mean for combination-therapy infringement risk?
Dependent claim 3
- “further comprising administering an additional pharmaceutical agent.”
Dependent claim 4
- The additional agent is selected from a list that spans a wide oncology toolbox: cytotoxics (e.g., cyclophosphamide, doxorubicin), targeted agents (e.g., dasatinib, erlotinib, lapatinib, osimertinib is not shown, but many others are), biologics/antibodies (e.g., rituximab, bevacizumab, trastuzumab), hormones (e.g., tamoxifen), immune modulators, and supportive hematopoietic growth factors (e.g., filgrastim, pegfilgrastim, epoetins).
- The list is not limited to lymphoma therapies. It reads like the patent owner anticipated combination regimens broadly.
Legal and practical effect
- The combination claims increase exposure for:
- label-directed NHL regimens that pair the claimed drug with one of the listed agents, and
- off-label combinations if the claim is proven to cover the method-of-treatment steps used in the real world (method claims do not require FDA label language to be infringed, but evidence of actual administration is central).
Consequence for generics and biosimilars
- A generic maker that only sells the active alone could aim to reduce risk by avoiding known combination protocols that include the listed “additional agents.” Still, claim 1 remains independent and can be asserted for monotherapy administration.
Which additional agents are explicitly listed in claim 4 that matter most for NHL regimen risk?
From your provided list, several agents are commonly used in NHL combination regimens or adjacent oncology protocols. Examples include:
- Rituximab (explicitly listed)
- Cyclophosphamide (explicitly listed)
- Doxorubicin (explicitly listed)
- Fludarabine (explicitly listed)
- Bendamustine (explicitly listed)
- Methotrexate (explicitly listed)
- Etoposide (explicitly listed)
- Vincristine (explicitly listed)
- Platinum agents like cisplatin and carboplatin (explicitly listed)
- Ibrutinib / acalabrutinib are not shown in the excerpt you provided; the list shows many modern oncology drugs but not every class member.
- Lenalidomide is listed
- Dasatinib is listed
- Everolimus is listed
- Immunotherapies like ipilimumab and nivolumab are not shown; pembrolizumab is not shown. (The list includes multiple immune biologics, but the excerpt is what governs the claim language.)
Because claim 4 is an enumerated “selected from” list, infringement depends on whether the accused regimen includes one of the listed “additional pharmaceutical agents.”
What is the enforceable scope relative to the chemical entity: how does “dihydrochloride salt or solvate/hydrate/tautomer” affect design-around?
Design-around pressure points
- Salt form: Claim 1 covers the dihydrochloride salt (and related solid forms via solvate/hydrate/tautomer language). A design-around typically targets:
- a different salt (e.g., other counterions) and
- avoiding forms that are argued to be a solvate/hydrate/tautomer of the dihydrochloride salt.
- Solid-state control: A manufacturer can attempt to use:
- an alternative solid state that is not a claimed solvate/hydrate/tautomer, or
- a non-crystalline form to avoid claim 2.
- Doctrine of equivalents (litigation-dependent): Claim construction may still evaluate whether a non-labeled form is effectively within the scope. In practice, salt/solid-state disputes are technical and heavily driven by analytical characterization (DSC, XRPD, vapor sorption, NMR/IR for solvates).
What patents typically surround US 9,636,344 for this drug class and how does that shape the landscape?
Claim-type neighborhood (typical)
Even without a full docket in the prompt, the provided claim text indicates this patent is part of a common IP cluster:
- a foundational compound patent family (core structure),
- one or more salt/polymorph/crystal form patents,
- one or more formulation patents (tablets, capsules, amorphous dispersions, particle-size control),
- one or more method-of-use patents for specific tumor indications (here: NHL),
- one or more combination therapy patents (here: broad additional-agent list).
How this matters for FTO and licensing
- If the compound is already covered by earlier patents, 9,636,344 may be a later-expiring “second-layer” right tied to a specific use and salt form.
- If earlier patents expire, 9,636,344 can still block entry through method infringement when the approved or marketed regimen involves the claimed drug entity used for NHL.
When does US Patent 9,636,344 lose exclusivity? How do expiration and litigation timing typically drive generic risk?
Your prompt provides only claim text, not:
- filing date,
- priority date,
- prosecution history,
- PTA/adjustments,
- or whether the patent is terminally disclaimed.
Without those, exact expiration and exclusivity timing cannot be stated accurately.
What is the Orange Book status of US 9,636,344 and what does it imply for Paragraph IV challenges?
Your prompt does not provide:
- the reference listed drug (RLD),
- NDA/BLA numbers,
- Orange Book listing status,
- or whether the patent is listed for the relevant strength/dosage form.
Without those details, the Orange Book / Paragraph IV pathway cannot be mapped to this patent with accuracy.
How strong is the patent estate for this NHL method claim based on claim construction features?
Strength indicators embedded in your claim text
- Single active anchor: Claim 1 is anchored to one specific chemical: the named dihydrochloride species. That increases clarity for infringement: the accused product must contain/ deliver that entity.
- Broad “patient in need thereof” language: The method claim is not confined to a specific dosing regimen or a specific line of therapy.
- Expanded solid-state coverage: Inclusion of solvate/hydrate/tautomer increases the chance that physical- form variability in commercial manufacturing still maps back to the claimed chemical category.
- Combination claim list is broad: Claim 4’s “additional agent selected from” list can broaden the scenarios where combination regimens infringe. Broad lists are harder to avoid in real-world prescribing.
Common attack vectors
- Written description / enablement: Particularly for broad combination lists and NHL breadth.
- Novelty/obviousness: Prior art on:
- known treatment of NHL using the same active compound salt, and
- known combinations that include one of the listed additional agents.
- Claim indefiniteness: Less likely given the provided claim language is specific.
What generic entry risks exist for this patent if the active is off-patent except for method use?
Scenario structure
- If generic manufacturers can market the drug but method claims remain enforceable, the principal risk is not “generic drug approval blocked,” but “label/regimen and induced infringement exposure.”
- Because claim 4 lists an extensive set of “additional agents,” a generic entrant faces higher risk if:
- it is marketed for NHL combinations in practice, or
- it supplies the drug with knowledge that it will be used in infringing NHL combinations.
Practical risk management
- Label positioning, REMS/communications, and distribution strategy can mitigate induced infringement risk, but they do not eliminate direct infringement by physicians and patients.
How does US 9,636,344 compare with typical NHL method patents in small-molecule oncology?
Claim 1 vs typical “class genus” claims
- Many oncology method patents claim broad “therapeutically effective” treatment using a class of inhibitors. Here, claim 1 is not a broad genus. It is a specific chemical and salt. That:
- reduces ambiguity in infringement,
- increases design-around options via different salt forms or different tautomers that are argued not to be covered,
- shifts litigation toward chemical characterization rather than medical claim boundaries.
Claim 4 breadth vs typical narrow combination claims
- Many combination patents are limited to one regimen or two agents. Claim 4’s long list expands infringement permutations but also raises vulnerability to prior art combinations and to enablement/written description challenges for every listed agent in combination.
Which manufacturing/IP barriers typically matter most for this kind of salt-based method claim?
Barrier categories
- Solid-state control: ensuring the delivered form is not argued to be a solvate/hydrate/tautomer of the claimed dihydrochloride.
- Analytical proof: proving non-infringement frequently turns on XRPD patterns, Raman/IR spectra, DSC thermograms, gravimetric sorption, and salt form identification under relevant humidity/temperature conditions.
- Process impurities and phase transformations: even if the intended salt differs, the manufacturing process or storage conditions can cause conversion to a dihydrochloride-related form that can trigger infringement arguments.
Key Takeaways
- US Patent 9,636,344 is a non-Hodgkin’s lymphoma method-of-treatment patent tied to a specific 2-amino-dihydroimidazo[1,2-c]quinazoline-5-yl pyrimidine-5-carboxamide dihydrochloride entity (plus solvate/hydrate/tautomer forms).
- Claim 2 narrows to crystalline form but does not remove the broader coverage in claim 1.
- Claim 3/4 creates meaningful combination regimen exposure because the additional agent list is extensive and includes widely used NHL and oncology drugs such as rituximab, cyclophosphamide, doxorubicin, bendamustine, fludarabine, and methotrexate.
- The litigation and design-around battleground is likely to center on whether the accused product delivers the claimed dihydrochloride (or covered solvate/hydrate/tautomer), and secondarily on whether the real-world administration is for non-Hodgkin’s lymphoma and includes a listed combination agent.
FAQs
1) What activities would most directly infringe US 9,636,344?
Administering (or causing administration) of the claimed di-hydrochloride salt (or covered solvate/hydrate/tautomer) to an NHL patient, including combined administration with one of the enumerated additional agents.
2) Can a manufacturer avoid claim 2 by selling an amorphous form?
Potentially for claim 2, yes, but claim 1 can still apply if the amorphous form is argued to be within the covered salt/solvate/hydrate/tautomer category.
3) Does the combination claim require the additional agent to be FDA-labeled for NHL?
The claim text requires an “additional pharmaceutical agent” selected from the list; infringement generally focuses on the actual administration to an NHL patient rather than label language.
4) What is the main technical evidence used to fight a dihydrochloride salt infringement allegation?
Solid-state characterization to show the supplied material is not the claimed dihydrochloride and not a claimed solvate/hydrate/tautomer under relevant conditions.
5) How does the breadth of the additional-agent list affect patent validity risk?
Broad enumerated combinations can increase prior-art overlap and raise enablement/written description scrutiny across the full list, depending on the patent’s disclosed support.
References
- United States Patent 9,636,344.
More… ↓
⤷ Start Trial
|
